<DOC>
	<DOC>NCT01404325</DOC>
	<brief_summary>This trial will evaluate the efficacy of Everolimus in combination with a centre specific standard immunosuppressive regimen versus a standard immunosuppressive regimen concerning kidney function in lung transplant recipients.</brief_summary>
	<brief_title>Efficacy of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<criteria>Inclusion criteria: Adult recipients of de novo cadaveric lung transplants Exclusion criteria: Patients with thrombocytopenia (platelets &lt;100,000/mm³), with an absolute neutrophil count of &lt;1,500/mm³ or leucopenia (leucocytes &lt;3000/mm³), with anemia with Hb &lt; 8g/dl at time of screening Patients with uncontrolled hypercholesterolemia (&gt;330mg/dL; &gt;9mmol/L) or hypertriglyceridemia (&gt;300 mg/dL; &gt;8.5 mmol/L) at time of screening Patients with a history of malignancy of any organ system, treated or untreated, during the last five years, whether or not there is evidence of local recurrence or metastases, except squamous or basal cell carcinoma of the skin Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Lung transplantation</keyword>
	<keyword>everolimus</keyword>
	<keyword>kidney function</keyword>
</DOC>